Valuation: Spruce Biosciences, Inc.

Market Cap 131M 117M 109M 99.3M 187M 12.63B 189M 1.32B 511M 6.46B 493M 483M 20.72B P/E 2026 *
-1.78x
P/E 2027 * 51x
Enterprise Value 67.57M 60.04M 56.03M 51.07M 96.32M 6.5B 97.22M 678M 263M 3.32B 254M 248M 10.66B EV / Sales 2026 *
-
EV / Sales 2027 * 0.01x
Free-Float
90.06%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2022-01-02
Director of Finance/CFO 43 2020-04-30
Chief Tech/Sci/R&D Officer 59 2026-07-26
Director TitleAgeSince
Chairman 73 2017-03-31
Director/Board Member 54 2017-09-30
Director/Board Member 67 2020-09-08
Date Insider Type Main position Quantity % Market Cap. Importance
7/27/26 Free

Chief Technology Officer

13,000 0.4723%
6/30/26 Free

Chief Executive Officer

266 0.0249%
5/21/26 Free

Director

1,700 0.1588%
Change 5-day change 1-year change 3-year change Capi.($)
+2.10%-6.18% - - 131M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average +0.01%-1.15%+52.63%+128.54% 39.07B
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2026 *2027 *
Net sales - 78.7M 69.93M 65.26M 59.49M 112M 7.57B 113M 790M 306M 3.87B 295M 289M 12.41B
Net income -59.04M -52.46M -48.96M -44.63M -84.17M -5.68B -84.95M -593M -230M -2.9B -222M -217M -9.31B -7.9M -7.02M -6.55M -5.97M -11.26M -759M -11.37M -79.28M -30.72M -388M -29.66M -29.02M -1.25B
Net Debt -63.8M -56.69M -52.91M -48.22M -90.95M -6.13B -91.8M -640M -248M -3.14B -240M -234M -10.06B -130M -116M -108M -98.49M -186M -12.53B -187M -1.31B -507M -6.4B -489M -479M -20.55B
Logo Spruce Biosciences, Inc.
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. It has a diverse portfolio of product candidates addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options. Its pipeline consists of TA-ERT, Tildacerfont and Cortibon, and SPR202. TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. Tildacerfont has the potential to address hyperactive brain corticotropin-releasing factors neurotransmission and aberrant functioning of the hypothalamus-pituitary-adrenal axis in patients with MDD. SPR202 focuses on the treatment of Congenital Adrenal Hyperplasia and other indications.
Employees
22
Date Price Change
26-10-02 US$45.71 +2.10%
26-10-01 US$44.77 -7.84%
26-09-30 US$48.58 +2.77%
26-09-29 US$47.27 -0.51%
26-09-28 US$47.51 -2.48%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
45.71USD
Average target price
148.00USD
Spread / Average Target
+223.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRB Stock